Intratumoural administration of a mouse-selective STING agonist, 5,6-dimethylxanthenone-4acetic acid (DMXAA), was shown to generate potent T cell responses in multiple tumour models, including B16.SIY and methylcholanthrene (MCA)-induced sarcomas, resulting in tumour rejection in the majority of mice [154,155]. Here, STING1 is linked to neoplasm.